“This financing will allow Atriomx to pursue the tremendous opportunity to transform the diagnosis and treatment of atrial fibrillation stemming from the application of novel AF detection and characterization capabilities to data that can be collected non-invasively,” said Duke Rohlen, CEO of Ajax Health and Zeus Health.
Request Information
Copyright © 2025 Medical Device News Magazine, a division of PTM Healthcare Marketing, Inc. All Rights Reserved
Hours:
Monday – Friday 8 am – 5 pm
Florida / New York
Phone: 561.316.3330